ALK is a critical therapeutic target, as its alterations (mutations, amplifications, and rearrangements) drive tumor development by activating oncogenic pathways, including MAPK/ERK, JAK-STAT, PI3K-Akt, and PLCγ, promoting tumor cell proliferation, survival, and progression [57]. This evidence concerns the gene SOAT1 and neoplasm.